In 2010, Congress approved the Biologics Price Competition and Innovation Act (BPCIA), creating an abbreviated approval pathway for biosimilars. While several have been approved, biosimilars have been met with increasingly complex and fortified patent estates—escalating the number of legal challenges launched against them.
Join us as our panelists lead a three-part in-depth discussion of biologics:
To register or for more information, please contact Tara Graves.
CLE credit: CLE credit in CA, FL, IL, NY, PA, TX, and VA (and in NJ via reciprocity) is currently pending approval.